Abstract
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the Delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Because of their high efficiency, remarkable stability, resilience to nebulization, and low cost of production, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
Keywords: COVID-19 pandemic; COVID-19 therapy; SARS-CoV-2 variant neutralization; aerosol therapy; anti-COVID-19 antibody; human single-chain antibody; inhalation; intranasal administration; phage display.
【저자키워드】 COVID-19 pandemic, aerosol therapy, intranasal administration, inhalation, phage display, COVID-19 therapy, SARS-CoV-2 variant neutralization, anti-COVID-19 antibody, human single-chain antibody, 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Resilience, Coronavirus disease 2019, coronavirus, antibody, COVID-19 pandemic, SARS-CoV-2 variant, Infection, Intervention, aerosol, animal models, severe acute respiratory syndrome Coronavirus, delta variant, Spike protein, stability, cells, SARS-CoV-2 spike protein, inhalation, single-chain variable fragment, COVID-19 therapy, cell-cell fusion, respiratory, epitope, Critical, intranasal, Immune status, administration, Efficiency, nebulization, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, subject, other variants, COVID-19 pathology, scFv, independent, neutralize, caused, inhibit, other variant, the SARS-CoV-2, 【제목키워드】 COVID-19, therapy, Human, SARS-CoV-2 variant, Neutralizing, antibody fragment,